{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.9","upperLimit":"7.8","value":"4.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"}],"units":"Participants"}],"description":"To determine the progression free survival with recurrent and metastatic adenoid cystic carcinoma treated with amivantamab.","dispersionType":"95% Confidence Interval","groups":[{"description":"Amivantamab weekly for the first cycle and biweekly thereafter.\n\nAmivantamab: Patients will receive amivantamab at 1050mg weekly for the first cycle and biweekly thereafter (1400mg for patients ≥80kg).","id":"OG000","title":"Amivantamab"}],"paramType":"MEDIAN","populationDescription":"3 patients were unevaluable and excluded from efficacy analyses for discontinuing amivantamab treatment before first restaging. Thus, 18 subjects were included for analyses.","reportingStatus":"POSTED","timeFrame":"Up to 27 months","title":"Progression Free Survival -Measured as Time of Treatment Allocation to Confirmed Progressive Disease or Death.","type":"SECONDARY","unitOfMeasure":"months"}